Transforming Biopharmaceutical Development Through Advanced Mass Spectrometry Data Analysis

By Ada Yee, Scientific Communications

This content is brought to you by Genedata, a Danaher Operating Company.

Biologic therapeutics continue to grow in complexity, and post‑translational modifications (PTMs) remain a defining factor in their stability, activity, and clinical performance. As the biopharmaceutical pipeline expands, deeper visibility into PTMs, especially glycosylation, is essential for ensuring safety and meeting regulatory expectations. Mass spectrometry has become central to this work, yet its application brings well‑known challenges: difficult sample preparation, incompatible chromatography conditions, heterogeneous data formats, and time‑intensive interpretation that risks obscuring low‑abundance variants.

Learn about the analytical bottlenecks that limit PTM characterization, with a focus on charge variant analysis and MS data harmonization, as well as how one global biopharma organization streamlined its workflows by unifying data processing, enabling higher sensitivity, faster turnaround, and richer structural insights.

Access the full case study to strengthen your analytical depth in PTM‑focused workflows.